SEC Form 4 · accession 0001209191-19-011179
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Isaac E. Ciechanover
Officer — Chief Executive Officer · Director
Period of report
Feb 15, 2019
Accepted (ET)
Feb 19, 2019 · 5:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 15, 2019 | F | 1,176 | $40.45 | D | 332,243 | D | |
| Common StockF2 | holding | — | — | — | 343,337 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares withheld to cover tax obligation from settlement of vested restricted stock units.
- F2Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.